Opendata, web and dolomites

NGN-PET SIGNED

Modelling Neuron-Glia Networks into a drug discovery platform for Pain Efficacious Treatments - Sofia ref.: 116072

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NGN-PET project word cloud

Explore the words cloud of the NGN-PET project. It provides you a very rough idea of what is the project "NGN-PET" about.

cellular    rat    co    pet    assays    throughput    vitro    ipscs    therapies    pose    cells    demands    life    nerve    compound    identification    tool    cultures    academic    mechanism    recapitulate    situation    expertise    translation    disciplinary    interactions    quality    patients    np    models    pharmaceutical    chronic    treat    interdisciplinary    altered    circuitry    nociceptors    poorly    subsequently    glial    hts    injury    central    interplay    forming    translate    industrial    treatments    frequently    activates    screening    solutions    neuropathic    drug    model    chemotherapy    neuronal    components    neuron    predictive    decipher    validation    carefully    microglia    cell    schwann    tools    peripheral    mechanisms    understand    discovery    stem    chronification    vivo    technologies    underlying    therapeutic    ngn    knowhow    preclinical    interrogated    pathological    platforms    molecular    basis    disease    team    human    pain    hence    builds    neurons    rodent   

Project "NGN-PET" data sheet

The following table provides information about the project.

Coordinator
AXXAM SPA 

Organization address
address: VIA MEUCCI 3
city: BRESSO MILANO
postcode: 20091
website: www.axxam.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://ngn-pet.com/
 Total cost 3˙050˙000 €
 EC max contribution 1˙500˙000 € (49%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2015-07-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2017
 Duration (year-month-day) from 2017-04-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AXXAM SPA IT (BRESSO MILANO) coordinator 450˙000.00
2    KING'S COLLEGE LONDON UK (LONDON) participant 450˙000.00
3    LIFE AND BRAIN GMBH DE (BONN) participant 450˙000.00
4    NATURWISSENSCHAFTLICHES UND MEDIZINISCHES INSTITUT AN DER UNIVERSITAET TUEBINGEN DE (REUTLINGEN) participant 150˙000.00
5    ESTEVE PHARMACEUTICALS, SA ES (BARCELONA) participant 0.00
6    GRUNENTHAL GMBH DE (AACHEN) participant 0.00

Map

 Project objective

Chronic Neuropathic Pain is frequently associated with peripheral nerve injury or disease. Peripheral injury activates both neuronal and glial components of the peripheral and central cellular circuitry. While it is widely known that the subsequently altered interactions between neurons and glial cells contribute to pain development and to its chronification, the underlying mechanisms are poorly understood. Developing mechanism-based therapies targeting neuron-glial interactions to treat chronic pain will be crucial for improving the quality of life of many patients. Hence the development of novel therapeutic solutions represents a major challenge that demands a multi-disciplinary approach to decipher and understand pathological mechanisms and to translate them into predictive tools for drug development. The NGN-PET consortium addresses this challenge by forming a highly interdisciplinary team that builds upon expertise in areas of academic research on pain mechanisms, industrial knowhow on human stem cell-based tool development, HTS technologies and drug discovery. To achieve its goal we will develop preclinical model systems and assays which recapitulate the human in vivo situation and which can be interrogated for the identification, validation of molecular targets and the development new treatments. A focus of the project will be chemotherapy induced NP and the interplay between nociceptors, microglia and Schwann cells. NGN-PET will carefully characterize rodent in vivo and in vitro models to identify these mechanisms, and will develop rat and human iPSCs based in vitro systems of neuron-glial co-cultures that can be interrogated for targets and used for compound identification and validation. NGN-PET will thus pose the basis for the translation of these model systems into high throughput screening platforms for pharmaceutical research and drug discovery.

 Deliverables

List of deliverables.
Interim dissemination and outreach report Documents, reports 2020-04-08 22:25:47
Data Management Plan Documents, reports 2020-04-08 22:25:47

Take a look to the deliverables list in detail:  detailed list of NGN-PET deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NGN-PET" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NGN-PET" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RespiriNTM (2019)

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Read More